Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf349 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Tal Etan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel. Hauptthemen laut MEDLINE: Gastritis, Duodenitis, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment. While generally well-tolerated, some immune-related adverse events (ir-AEs) can impact patient care, highlighting the need for accurate diagnosis. Immunotherapy-related gastritis and duodenitis (ir-GD) is a rare ir-AE. Due to its low incidence and nonspecific symptoms, standardized diagnostic criteria and evidence-based treatment guidelines are lacking.
Methods
We conducted a retrospective analysis of patients undergoing esophagogastroduodenoscopy (EGD) while receiving ICI. Our diagnostic criteria for ir-GD required at least two of three gastritis or duodenitis (GD) criteria (symptoms, EGD findings, or microscopic findings) along with at least one ICI-related criterion. Patients with ir-GD were compared to those without ir-GD.
Results
Of 2553 patients treated with ICI between 2017 and 2023, 62 (2.4%) underwent EGD, of whom nine (0.4%) met the ir-GD diagnostic criteria. Nine other patients (0.4%) had GD unrelated to ICI. Notably, three of the nine patients (33%) with ir-GD had preexisting inflammatory gastrointestinal conditions, compared to two of 53 patients (4%) in the non-ir-GD cohort (P = .019). Patients with ir-GD were significantly more symptomatic (100% vs 58%, P = .009). However, no single symptom was specific to ir-GD. While eight of nine (89%) patients with ir-GD were treated with proton pump inhibitors, only three (33%) required corticosteroids. Symptom resolution occurred in all patients, and three patients successfully underwent rechallenge. Conclusion ir-GD is a rare ir-AE that can be challenging to distinguish from GD caused by other etiologies. Once diagnosed, clinicians may consider nonsteroidal treatment approaches in mild cases and, in selected cases, even ICI rechallenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
- The Tel Aviv University Faculty of Medicine recently changed its name from the Sackler Faculty of Medicine to the Gray Faculty of Medicine, Tel Aviv 69978, Israel.
- School of Medicine, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel- Aviv 6997801, Israel.
- Department Pathology, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
ORCID-Profile: Tal Etan, Mor Miodovnik, Yasmin Leshem
Zitieren
APA
Etan, T., Bar-Yishay, I., Greenberg, A., Brazowsky, E., Brezis, M. R., Shachar, S. S., Miodovnik, M., Wolf, I., & Leshem, Y. (2025). Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge. The Oncologist. https://doi.org/10.1093/oncolo/oyaf349
Vancouver
Etan T, Bar-Yishay I, Greenberg A, Brazowsky E, Brezis MR, Shachar SS, et al. Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge. The Oncologist. 2025. doi:10.1093/oncolo/oyaf349
BibTeX
@article{Etan2025,
author = {Etan, Tal and Bar-Yishay, Iddo and Greenberg, Ariel and Brazowsky, Eli and Brezis, Miriam R and Shachar, Shlomit Strulov and Miodovnik, Mor and Wolf, Ido and Leshem, Yasmin},
title = {Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf349}
}
EUVIMED